Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma

被引：13
|
作者：
Weber, Donna [1 ]
Knight, Robert [2 ]
Chen, Christine [3 ]
Spencer, Andrew [4 ]
Yu, Zhinuan [2 ]
Zeldis, Jerome [2 ]
Olesnyckyj, Marta [2 ]
Dimopoulos, Meletios [5 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Celgene Corp, Summit, NJ USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[5] Univ Athens, Sch Med, GR-11527 Athens, Greece
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.412.412
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
412
引用
收藏
页码：128A / 128A
页数：1
相关论文
共 50 条
  • [1] Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Siegel, David S.
    Dimopoulos, Meletios A.
    Ludwig, Heinz
    Facon, Thierry
    Goldschmidt, Hartmut
    Jakubowiak, Andrzej
    San-Miguel, Jesus
    Obreja, Mihaela
    Blaedel, Julie
    Stewart, A. Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 728 - +
  • [2] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Spencer, Andrew
    Attal, Michael
    Prince, H. Miles
    Harousseau, Jean-Luc
    Dmoszynska, Anna
    San Miguel, Jesus
    Hellmann, Andrzej
    Facon, Thierry
    Foa, Robin
    Corso, Alessandro
    Masliak, Zvenyslava
    Olesnyckyj, Marta
    Yu, Zhinuan
    Patin, John
    Zeldis, Jerome B.
    Knight, Robert D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21): : 2123 - 2132
  • [3] Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Dabkara, Deepak
    Bajpai, Jyoti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (03) : 10 - 13
  • [4] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Nikhil C Munshi
    Constantine Mitsiades
    Paul G Richardson
    Kenneth C Anderson
    Nature Clinical Practice Oncology, 2008, 5 : 374 - 375
  • [5] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Munshi, Nikhil C.
    Mitsiades, Constantine
    Richardson, Paul G.
    Anderson, Kenneth C.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 374 - 375
  • [6] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [7] Erratum: Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Nikhil C Munshi
    Constantine Mitsiades
    Paul G Richardson
    Kenneth C Anderson
    Nature Clinical Practice Oncology, 2008, 5 : 493 - 493
  • [8] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Shinsuke Iida
    Takaaki Chou
    Shinichiro Okamoto
    Hirokazu Nagai
    Kiyohiko Hatake
    Hirokazu Murakami
    Toshiyuki Takagi
    Kazuyuki Shimizu
    Henry Lau
    Kenichi Takeshita
    Masaaki Takatoku
    Tomomitsu Hotta
    International Journal of Hematology, 2010, 92 : 118 - 126
  • [9] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Iida, Shinsuke
    Chou, Takaaki
    Okamoto, Shinichiro
    Nagai, Hirokazu
    Hatake, Kiyohiko
    Murakami, Hirokazu
    Takagi, Toshiyuki
    Shimizu, Kazuyuki
    Lau, Henry
    Takeshita, Kenichi
    Takatoku, Masaaki
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 118 - 126
  • [10] Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
    Wang, Michael
    Dimopoulos, Meletios A.
    Chen, Christine
    Cibeira, M. Teresa
    Attal, Michel
    Spencer, Andrew
    Rajkumar, S. Vincent
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome B.
    Knight, Robert D.
    Weber, Donna M.
    BLOOD, 2008, 112 (12) : 4445 - 4451
12345